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Prognostic prediction 
by hypermetabolism varies 
depending on the nutritional 
status in early amyotrophic lateral 
sclerosis
Ryutaro Nakamura1, Mika Kurihara2, Nobuhiro Ogawa1, Akihiro Kitamura1, 
Isamu Yamakawa1, Shigeki Bamba2, Mitsuru Sanada1, Masaya Sasaki2 & 
Makoto Urushitani1*
To examine whether hypermetabolism could predict the prognosis of early amyotrophic lateral 
sclerosis (ALS) patients with differing nutritional profiles. This single-center, retrospective study 
examined the prognosis of ALS patients with hypermetabolism in relation to their nutritional status 
at hospitalization. The metabolic state was estimated by the ratio of measured resting energy 
expenditure (mREE) to lean soft tissue mass (LSTM) (mREE/LSTM), wherein patients with ratios ≥ 38 
were defined as hypermetabolic. Malnutrition was defined as %ideal body weight < 0.9. Forty-eight 
patients were enrolled in this study. The hypermetabolic group had shorter survival in the normal-
weight group but more prolonged survival in the malnutrition group. Multiplication of nutritional 
and metabolic factors, such as [(body mass index (BMI) − 19.8) × (mREE/LSTM − 38)], designated as 
BMI-muscle metabolism index (BMM index), successfully predicted the prognosis in the group with 
a high BMM index (≥ 1), which showed shorter survival and a faster rate of weight loss and functional 
decline. Multivariate analysis using the Cox model showed high BMM index was an independent poor 
prognostic factor (hazard ratio: 4.05; p = 0.025). Prognostic prediction by hypermetabolism varies 
depending on the nutritional status in ALS, and the BMM index is a consistent prognostic factor.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive degenera-
tion of the upper and lower motor neurons, with a median survival time of two to four  years1. ALS is caused by 
diverse pathomechanisms, including genetic defects and dysregulated cellular machinery, such as proteostasis, 
RNA metabolism, mitochondria, excitotoxicity, and  neuroinflammation2–5. Although disease-modifying drugs 
are underway, the therapeutic efficacy of currently available drugs––riluzole and edaravone––is unfortunately 
limited.
Evidence regarding the significance of non-pharmacological treatment is accumulating, indicating that it can 
improve the quality of life and the progression or survival of ALS. Early introduction of non-invasive positive 
pressure ventilation (NPPV), especially with cough assist devices, is reported to prolong the lifespan of  ALS6. 
In addition, a lower body mass index (BMI) less than 18.5 at the first visit to the neurologists has been well-
recognized as a poor prognostic factor, and a high-calorie diet effectively slows ALS progression, especially 
in rapid  progressors7,8. Surprisingly, in rapidly progressing ALS, a fat-dominant high-calorie diet inhibits the 
elevation of serum neurofilament-L (NFL), a compelling biomarker of neuronal  damage7. Despite these lines 
of clinical evidence, the mechanism by which the reduction of body weight or the intake of a high-calorie diet 
confers protection in ALS is not well known.
Previous studies have shown that metabolism and nutritional status play an essential role in the progres-
sion of ALS.  Hypermetabolism9–11, low body fat  percentage12, and low fat-free  mass13 were poor prognostic 
factors, as confident as serum creatine phosphokinase (CPK), creatinine, albumin, and ferritin, as previously 
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 reported1,3,14,15. Patients with weight loss had shorter survival time, and weight loss also affected functional out-
comes after  tracheostomy16,17. Although not evident, subthalamic dysfunction, dysregulated autophagy, impaired 
mitochondrial function, and  excitotoxicity4,18 are implicated in the hypermetabolism of ALS  patients9, which 
leads to weight  loss19.
Identifying the energy source is essential when analyzing metabolism. ALS patients have impaired glucose 
tolerance at the early stage, and free fatty acids are higher in such patients than in those with normal glucose 
 tolerance20. It was reported that the energy production pathway changed from glycolytic to lipid metabolism 
during starvation in ALS mice, in a process called “fuel switch”4. This indicates that lipids may be the primary 
fuel in patients with malnutrition as well as ALS mice, although no studies examined changes in metabolism 
in response to the nutritional status of humans. Elevated levels of total cholesterol and low-density lipoprotein 
cholesterol (LDL), and a higher LDL/ high-density lipoprotein cholesterol (HDL) ratio has been associated 
with longer  survival21,22, which might indicate the benefit of lipid metabolism. Therefore, we retrospectively 
examined our institutional cohort to test the hypothesis that the impact of hypermetabolism on survival might 
differ depending on the nutritional status.
Materials and methods
Patients and ethical considerations. This is a single-center retrospective study of ALS patients admitted 
to Shiga University of Medical Science Hospital from March 2018 to February 2021 for close investigation, the 
introduction of therapeutic drugs and NPPV, or percutaneous endoscopic gastrostomy (PEG). We collected the 
data from the first admission in this period. All patients fulfilled the revised El Escorial criteria for probable or 
definite  ALS23 and underwent indirect calorimetry. We excluded patients who were younger than 49 years old, 
who had used mechanical ventilation, including NPPV, and who had experienced PEG until this admission to 
avoid the influence of metabolism analysis. This study was approved by the Ethics Committee of Shiga Univer-
sity of Medical Science Hospital (approval no.: R2020-171). We applied Opt-out method and obtained informed 
consent on this study, which have been performed in accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki and its later amendments. The participants have consented to the submission of 
this study to the journal.
Clinical parameters. Nutritional status was estimated by BMI at this admission, and we calculated 
the percent ideal body weight (%IBW), using the following formula: %IBW = body weight at this admis-
sion/22 × ([patient’s height in meters] ^2). We defined malnutrition as %IBW < 0.9, according to a previous 
 report24. We evaluated the monthly rate of BMI decline since onset to this admission (ΔBMI), using the fol-
lowing formula: (BMI at this admission − premorbid BMI)/(time since onset in months). To assess the disease 
progression, we calculated the monthly decline rate of the Revised Amyotrophic Lateral Functional Rating Scale 
(ALSFRS-R) score from onset to this admission (ΔALSFRS-R), using the following formula: (48 − ALSFRS-R at 
this admission)/(time from onset to this admission in months)25. We also evaluated the following factors: age, 
sex, body region affected at the onset, excess weight loss (more than 10% compared to the body weight before 
the illness), and time since the first visit. To assess the influence of treatment on survival time, we collected the 
data of using NPPV and PEG tube feeding.
Energy metabolism and body composition. We collected data on the resting energy expenditure 
(REE) and respiratory quotient (RQ), which were measured by indirect calorimetry (Aeromonitor AE310S, 
Minato Medical Science Co., Ltd.). Indirect calorimetry was performed for 10 min in the morning after the 
patient had fasted overnight and rested in the supine position on a bed for 30  minutes26. We calculated the RQ as 
carbon dioxide production divided by oxygen uptake (VCO2/VO2) and calculated the measured REE (mREE; 
kcal) using the Weir equation without urinary  nitrogen27. We estimated the predicted REE (pREE; kcal) via the 
Harris-Benedict Eq. 28. To evaluate body composition, we collected the data of lean soft tissue mass (LSTM; kg), 
body fat percentage (%), and skeletal muscle index (SMI; kg/m2), which were measured by bioelectrical imped-
ance analysis with a body composition analyzer (InBody S10; InBody, Tokyo, Japan). The bioelectrical imped-
ance analysis was performed concurrently with the indirect calorimetry.
As for the definition of hypermetabolism, we used mREE/LSTM rather than mREE/pREE9,10 because pREE 
tends to be overestimated in Japanese  people29. Although previous reports used mREE/fat-free mass as a factor 
associated with  hypermetabolism9,30,31, we replaced fat-free mass with LSTM expecting to get a more accurate 
evaluation of metabolism per lean tissue because LSTM could discriminate lean tissue from bone quantity and 
be effective for assessing skeletal muscle  mass32,33.
We defined hypermetabolism as mREE/LSTM ≥ 38 kcal/kg, considering the percentage of patients with hyper-
metabolism. The number of patients with mREE/LSTM ≥ 38 was 20/46 (43.4%) in our cohort, while the number 
of patients with hypermetabolism was 24/58 (41.3%) in the study by  Steyn10, which confirmed the validity of the 
cut-off value. We defined the high body fat percentage as more than 25% in men and 30% in women. For the RQ, 
we determined the cut-off value as 0.85, because it is 0.7 for fat and 1.0 for  carbohydrates34.
Other biomarkers. We collected the following data of respiratory function tests measured by spirometry: 
%peak expiratory flow (%PEF; %), and %vital capacity (%VC; %). We extracted the following data of blood bio-
markers on the day closest to that in which indirect calorimetry was performed: LDL; mg/dl, and fasting blood 
sugar (FBS; mg/dl). We defined high LDL as LDL ≥ 100 according to a previous  report22.
Endpoints. We defined endpoints as the time of death or tracheotomy and survival time as the duration 
from onset to endpoints or censoring time. The censoring time for the follow-up was the end of February 2021.
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Statistical analysis. We classified patients by metabolic status dependent on their nutritional status. We 
used Fisher’s exact test or Mann–Whitney U test for data comparison between the hypermetabolic group and 
normally metabolic group depending on nutritional status. To estimate the absolute risks of hypermetabolism 
on survival depending on nutritional status, we used Kaplan–Meier curves and the log-rank test. Similarly, 
we determined high mREE/pREE as > 1.19 to validate it as a prognostic factor in different nutritional statuses. 
Furthermore, excess weight loss, body fat percentage, and LDL were assessed for stratification by using the 
Kaplan–Meier curves and the log-rank test. Kaplan Myer curves start below 100% survival when the endpoint 
occurs within one month after this admission. To investigate the association between the demographics and 
body fat percentage, mREE/LSTM, mREE/pREE, or RQ, we used the Spearman rank-correlation method. Vari-
ables are summarized as the median and interquartile range for continuous variables or frequency for categorical 
variables; missing values were excluded. Statistical analyses were two-sided, and p < 0.05 was considered signifi-
cant. All analyses were performed by using EZR version 1.53 (Saitama Medical Center, Jichi Medical University, 
Japan)35. To create figures, we used EZR and Microsoft Excel version 2016.
Result
Clinical characteristics and outcomes. Forty-eight patients were included in this study (25 men; 23 
women); body composition data were lacking in two male patients. The median mREE/LSTM of the male group 
was 35.9 kcal/kg (interquartile range 34.4 to 39.6), and that of the female group was 36.9 kcal/kg (interquartile 
range 34.5 to 42.3), which were not significantly different (p = 0.50). We classified patients by the metabolic state 
depending on nutritional status; the clinical profiles of which were summarized in Table 1. Age and sex were not 
significantly different between the hypermetabolic and normal metabolic groups in the normal-weight group 
Table 1.  Clinical characteristics and biomarkers. Bold font was used to strengthen the statistical significance. 
Data presented as median [Interquartile range]. (n) shows the number of patients in factors that have missing 
values. Due to missing values, the sum of the numbers in each group does necessarily equal the total number. 
IBW Ideal body weight, BMI Body mass index, ALSFRS-R Revised amyotrophic lateral functional rating scale, 
FBS Fasting blood sugar, LDL Low-density lipoprotein cholesterol, PEF Peak expiratory flow, VC Vital capacity, 
LSTM Lean soft tissue mass, REE Resting energy expenditure, mREE Measured REE, pREE Predicted REE, RQ 
Respiratory quotient, SMI Skeletal muscle index, PEG Percutaneous endoscopic gastrostomy, NPPV Non-
invasive positive pressure ventilation. *p value is based on Fisher’s exact test or Mann–Whitney U test. †Excess 
weight loss means more than 10% compared to the body weight before the illness.




p*Hyper (11) Normal (18) Hyper (9) Normal (8)
Age (years) 71 [65, 75] 73 [67, 75] 69 [61, 75] 0.62 71 [67, 74] 69 [63, 74] 0.81
Sex (female) 23/48 (48%) 5/11 7/18 1 5/9 6/8 0.62
Premorbid BMI 23.2 [20.1, 25.0] 24.5 [22.8, 25.4] 23.9 [23.32 26.5] 0.77 19.0 [18.6, 20.2] 20.0 [19.1, 22.4] 0.114
BMI at this 
admission 21 [19, 23] 22 [21, 23] 22 [21, 25] 0.64 19 [18, 19] 19 [17, 19] 0.96
ΔBMI (/M)  − 0.13 [− 0.25, 0.00]
 − 0.20 
[− 0.26, − 0.06]
 − 0.03 
[− 0.23, 0.00] 0.26
 − 0.01 
[− 0.19, 0.00]
 − 0.04 
[− 0.55, − 0.08] 0.114
Excess weight loss 
(yes)† 12/48 (25%) 3/11 5/18 1 1/9 3/8 0.29
Time since onset 
(M) 15 [8, 30] 10 [8, 15] 17 [11, 34] 0.065 24 [12, 31] 9 [8, 13] 0.048
Time since the 
first visit 2 [1, 5] 1 [1, 3] 1 [1, 6] 0.47 1 [0, 18] 2 [1, 4] 0.92
ALSFRS-R 39 [35, 43] 36 [32, 44] 40 [34, 45] 0.70 38 [36, 43] 41 [40, 42] 0.74
ΔALSFRS-R 0.59 [0.27, 0.91] 0.60 [0.34, 1.5] 0.42 [0.18, 0.77] 0.22 0.66 [0.19, 0.73] 0.66 [0.48, 0.91] 0.44
Bulbar type (yes) 12/48 (25%) 2/11 3/18 1 2/9 5/8 0.153
FBS (mg/dl) (n) 98 [86, 107] (40) 97 [91, 106] (10) 98 [89, 110] (16) 0.90 104 [89, 115] (6) 83 [83, 85] (6) 0.023
LDL (mg/dl) (n) 109 [96, 132] (40) 100 [85, 104] (10) 108 [92, 127] (15) 0.47 143 [117, 155] (8) 116 [101, 138] (6) 0.30
%PEF (%) (n) 77 [61, 91] (46) 70 [59, 88] (10) 90 [70, 103] (18) 0.175 85 [69, 99] (8) 65 [54, 75] (7) 0.046
%VC (%) (n) 87 [78, 94] (46) 85 [67, 95] (10) 91 [84, 100] (18) 0.175 81 [79, 90] (8) 81 [61, 89] (7) 0.72
Body fat (%) (n) 31.7 [26.2, 37.1] (46) 34.9 [30.4, 43.7] 30.3 [27.1, 36.4] 0.20 32.1 [27.7, 37.3] 27.2 [22.4, 31.0] 0.114
LSTM (kg) (n) 34 [29, 40] (46) 33 [28, 40] 38 [33, 44] 0.101 29 [24, 38] 31 [29, 35] 0.61
mREE/LSTM (n) 36.4 [34.4, 40.5] (46)
40.6 [39.4, 42.1] 
(11)
34.4 [33.5, 34.9] 
(18)  < 0.001
41.7 [39.5, 43.2] 
(9)
34.5 [34.1, 35.6] 
(8)  < 0.001
mREE/pREE 1.07 [1.00, 1.16] 1.12 [1.05, 1.25] 1.07 [0.99, 1.08] 0.044 1.08 [1.00, 1.15] 1.02 [0.97, 1.06] 0.28
RQ < 0.85 (yes) 29/48 (60%) 6/11 10/18 1 8/9 4/8 0.131
SMI (kg/m2) (n) 5.8 [4.7, 6.4] (46) 5.6 [4.5, 6.2] 6.4 [5.9, 7.1] 0.028 4.7 [3.7, 5.8] 5.1 [4.6, 5.8] 0.56
PEG (yes) 25/48 (52%) 8/11 5/18 0.027 7/9 4/8 0.035
NPPV (yes) 27/48 (57%) 7/11 9/18 0.71 7/9 4/8 0.34
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and the malnutrition group. The hypermetabolic normal-weight group had the following characteristics: higher 
mREE/pREE (p = 0.044), and lower SMI (p = 0.028). On the other hand, the hypermetabolic malnutrition group 
had a longer time since onset (p = 0.048), higher FBS (p = 0.023), and higher %PEF (p = 0.046).
The log-rank test showed that neither metabolic state nor nutrition state alone was a statistically independ-
ent prognostic factor (p = 0.53, p = 0.99, respectively). The hypermetabolic group had a shorter survival time 
in normal-weight patients (p = 0.009) but showed a trend of longer survival time in the malnutrition group 
(p = 0.066) (Fig. 1), which was also seen in the log-rank test for time since this admission (Supplemental Fig. 1). 
Of note, mREE/pREE alone was not a statistically significant prognostic factor among all patients (p = 0.43), the 
normal-weight group (p = 0.70), or the malnutrition group (p = 0.73) (Supplemental Fig. 2). As for other risk 
factors, high body fat and excess weight loss were good (p = 0.004) and poor (p < 0.001) prognostic factors for 
survival time (Fig. 2). Patients with low LDL had a propensity toward shorter survival, although the difference 
was not significant (p = 0.063). In the log-rank test for the survival time since this admission, patients with excess 
weight loss (p = 0.007) and low LDL (p < 0.001) had shorter survival, and patents with low body fat showed similar 
trend (p = 0.106) (Supplemental Fig. 3).
We examined demographics associated with RQ, mREE/LSTM, mREE/pREE, or body fat percentage. RQ was 
associated with ALSFRS-R (p = 0.013), time since onset (p = 0.003), body fat percentage (p = 0.017), and LSTM 
(p = 0.022) (Fig. 3). mREE/LSTM was positively associated with body fat percentage (rs = 0.36, p = 0.015), and 
Figure 1.  Comparison of survival rate between the hypermetabolic group and the normal metabolic group 
in all patients (a), the normal-weight group (b), the malnutrition group (c). Kaplan–Meier analyses and the 
log-rank test showed there was no difference in all patients (p = 0.53); however, the hypermetabolic group had 
a significantly shorter survival time in the normal-weight group (p = 0.009) and longer survival time in the 
malnutrition group (p = 0.066), although the difference was not significant.
Figure 2.  Comparison of survival rate between amyotrophic lateral sclerosis patients stratified by excess weight 
loss (a), body fat percentage (b), and low-density lipoprotein cholesterol (LDL) (c). Kaplan–Meier analyses and 
the log-rank test showed patients with excess weight loss (p < 0.001) and low body fat percentage (p = 0.004) had 
significantly shorter survival time. Patients with low LDL also had shorter survival time, although the difference 
was not significant (p = 0.063).
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negatively with BMI (rs =  − 0.29, p = 0.048), and LSTM (rs =  − 0.46, p = 0.002) (Supplemental Fig. 4). mREE/pREE 
was positively associated with LSTM (rs = 0.44, p = 0.002), and negatively with body fat percentage (rs =  − 0.42, 
p = 0.004). mREE/pREE was not associated with BMI (rs = 0.00, p = 0.99). Body fat percentage was positively 
correlated with BMI (rs = 0.38, p = 0.009) and negatively with LSTM (rs =  − 0.54, p < 0.001).
BMM index. The discrepant trends in survival times between the hypermetabolic patients in the normal-
weight and malnutrition groups led us to estimate the influence of hypermetabolism on survival and nutritional 
status. We tried to obtain the new evaluation plan named “BMI-muscle metabolism (BMM) index” via the fol-
lowing equation: (BMI − 19.8) × (mREE/LSTM − 38). We subtracted 19.8 from BMI because %IBW < 0.9 means 
BMI < 19.8. Since a BMI of 19.8 and a mREE/LSTM of 38 are normal values, the BMM index increases when 
both are more or less than average. We thus tested whether a high BMM index predicted a poor prognosis.
We determined the cut-off value of BMM Index with time-dependent receiver operating characteristic (ROC) 
 curves36, which confirmed that the BMM index predicted the incidence of endpoints within two years from the 
onset (AUC = 0.82), with a sensitivity of 0.77, and a specificity of 0.88 when the BMM index was higher than 
one (Fig. 4). Therefore, we determined the cut-off value of the BMM index as one and classified patients by this 
cut-off value into two groups. We used Fisher’s exact test and the Mann–Whitney U test to compare the two 
groups and summarized demographics and biomarkers (Table 2).
In the high BMM index group, ΔALSFRS-R (p = 0.003) and ΔBMI (p = 0.004) were higher and lower than that 
in the low BMM index group, respectively. Regarding biomarkers, the high BMM index group had lower LDL 
(p = 0.011) and lower %VC (p = 0.002) compared with those of the low BMM index group. The Kaplan–Meier 
analysis and log-rank test revealed that the high BMM index group had significantly shorter survival time 
Figure 3.  The association between demographics and respiratory quotient (RQ). RQ was significantly 
correlated with ALSFRS-R (a), lean soft tissue mass (b), body fat percentage (c), and time since onset (d). Rs 
means Spearman’s rank-correlation coefficient. p value is based on Spearman’s test.
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Figure 4.  The prognostic value of BMI-muscle metabolism index (BMM Index). Patients who died or 
underwent tracheostomy within 24 months from onset are presented as red circles, and the remaining patients 
are presented as black circles (a). The shaded area shows the body mass index-muscle metabolism (BMM) 
index ≥ 1 (a). Time-dependent receiver operating characteristic curve analysis shows that the BMM index 
strongly predicts the incidence of endpoints within two years from the onset (area under the curve = 0.82) (b).
Table 2.  Demographics and biomarkers. Bold font was used to strengthen the statistical significance. Data 
presented as median [Interquartile range]. (n) shows the number of patients in factors that have missing 
values. BMM BMI-muscle metabolism, BMI Body mass index, ALSFRS-R Revised amyotrophic lateral 
functional rating scale, LDL Low-density lipoprotein cholesterol, VC Vital capacity, REE Resting energy 
expenditure, mREE Measured REE, pREE Predicted REE, RQ Respiratory quotient, SMI Skeletal muscle index, 
PEG Percutaneous endoscopic gastrostomy, NPPV Non-invasive positive pressure ventilation. *p value is based 
on Fisher’s exact test or Mann–Whitney U test. † Excess weight loss means more than 10% compared to the 
body weight before the illness.
BMM index  < 1  ≥ 1
p*n 31 15
Age (years) 69 [62, 74] 73 [68, 75] 0.23
Sex (female) 15/31 (48%) 8/15 (53%) 1
BMI 21 [19, 23] 21 [19, 22] 0.57
ΔBMI(/M)  − 0.02 [− 0.19, 0.00]  − 0.25 [− 0.31, − 0.16] 0.004
Excess weight loss (yes)† 6/31 (19%) 6/15 (40%) 0.165
Time since onset (M) 17 [12, 32] 8 [8, 11] 0.005
ALSFRS-R 41 [36, 45] 38 [34, 42] 0.196
ΔALSFRS-R 0.44 [0.16, 0.72] 0.88 [0.59, 1.5] 0.003
Bulbar type (yes) 6/31 (19%) 6/15 (40%) 0.165
LDL (mg/dl) (n) 122 [102, 143] (27) 98 [91. 103] (12) 0.011
%VC (%) (n) 90 [82, 98] (30) 78 [55, 86] (14) 0.002
mREE/pREE 1.07 [1.00, 1.11] 1.06 [1.00, 1.21] 0.66
RQ < 0.85 (yes) 20/31 (65%) 8/15 (53%) 0.53
High-fat (yes) 22/31 (71%) 10/15 (67%) 1
Lean soft tissue mass (kg) 36 [31, 42] 31 [28, 37] 0.143
SMI (kg/m2) 6.0 [5.2, 6.8] 5.5 [4.5, 6.1] 0.073
PEG (yes) 14/31 (45%) 10/15 (67%) 0.22
NPPV (yes) 20/31 (65%) 7/15 (47%) 0.22
Endpoint (yes) 11/31 (35%) 10/15 (67%) 0.063
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compared with that of the low BMM index group (p < 0.001) (Fig. 5). To examine the effect of the BMM index 
on the survival time since onset or this admission, we performed Cox proportional hazards (PH) model with the 
following confounding factors: age, ALSFRS-R, bulbar type, excess weight loss, high BMM Index, and %VC. Mul-
tivariate analysis showed BMM index and excess weight loss were independent poor prognostic factors (Table 3).
Discussion
In this study we explored the effect of hypermetabolism on survival relative to the nutritional status of patients 
with ALS, and found that hypermetabolic patients with a normal-weight had shorter survival, whereas survival 
was longer in hypermetabolic patients with malnutrition. Of note,  Steyn10 and  He11 reported that hyperme-
tabolism is a clear predictor of poor prognosis, and  Bouteloup9 demonstrated similar results, although it was 
not statistically significant. Based on our results, the possible reason to explain these different statistics might 
be because the mean value of BMI in the Steyn paper was higher than that of the Bouteloup. The lower SMI 
and LSTM, a previously reported poor prognostic  factor13 (Table 1), could be the reason the prognosis of our 
hypermetabolic normal-weight group is worse than that of other groups.
Surprisingly, hypermetabolism was a better prognostic factor in the malnutrition group (Fig. 1). Lipid bio-
markers were characteristic in this group, which might contribute to the longer survival. The hypermetabolic 
malnutrition group had the highest median value of LDL among all the groups, and higher body fat percentage, 
which were good prognostic factors in previous studies. Indeed, patients with a high body fat percentage had 
longer survival in our study (Fig. 2), and the patients with high LDL showed a similar trend. It should be noted 
that the RQ was less than 0.85 in eight out of nine patients in this group (Table 1), and FBS was significantly 
Figure 5.  Comparison of survival rate between amyotrophic lateral sclerosis patients stratified by body mass 
index-muscle metabolism index (BMM index). The Kaplan–Meier analysis showed significant differences (log-
rank test, p < 0.001).
Table 3.  Cox proportional hazards model. Bold font was used to strengthen the statistical significance. HR 
Hazard ratio (95% confidence interval), BMM Body mass index-muscle metabolism, ALSFRS-R Revised 
amyotrophic lateral functional rating scale, VC Vital capacity. *p value is based on Cox proportional hazards 
model. † Excess weight loss means more than 10% compared to the body weight before the illness.
(A) Survival since onset (B) Survival since this admission
Adjusted HR p* Adjusted HR p*
BMM index  ≥ 1 versus < 1 4.05 (1.19–13.8) 0.025 5.90 (1.76–19.7) 0.004
Age 0.98 (0.89–1.07) 0.66 0.99 (0.89–1.09) 0.80
ALSFRS-R 1.05 (0.94–1.17) 0.37 0.99 (0.90–1.09) 0.82
Excess weight  loss† Yes versus no 3.07 (1.11–8.53) 0.031 2.95 (1.03–8.43) 0.043
Bulbar type Yes versus no 1.43 (0.52–4.00) 0.49 0.96 (0.30–3.01) 0.94
%VC 0.98 (0.94–1.02) 0.22 0.96 (0.92–1.00) 0.061
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higher in this group, which might indicate a lipid metabolism-shift from glucose  assumption34. Indeed, the RQ 
was associated with ALSFRS-R and time since onset, and it is intriguing to hypothesize that a “fuel switch” may 
underlie metabolic profiles in ALS  progression4. Furthermore, Steyn et, al. reported that high elevated fatty-acid 
oxidation increases whole-body energy expenditure and slows disease progression 37, which might support our 
results and indicate the contribution of hyper lipid metabolism for longer survival. Our findings caution against 
overestimation of hypermetabolism alone as a prognosis indicator.
Based on the possible involvement of skeletal muscles’ hypermetabolism in ALS  prognosis9,10, we proposed the 
equation “BMM index = (BMI − 19.8) × (mREE/LSTM − 38),” which successfully predicted the prognostic factor, 
regardless of nutritional states. In agreement with a previous  report38, our cohort demonstrated that weight loss 
of more than 10% was an independent poor prognostic factor. The rate of weight loss was faster in the high BMM 
index group; thus, the BMM index could be a valuable indicator to consider aggressive nutritional intervention, 
including PEG, at an early stage in clinical practice. High-fat or high-carbohydrate calorie supplementation is 
a matter of debate. Some reports suggested that high-fat calorie supplementation was a better nutritional treat-
ment in ALS  patients39,40, while others recommend high-carbohydrate calorie  supplementation41. For patients 
with chronic obstructive pulmonary disease who have impaired  CO2 emissions, a high-fat diet is recommended 
because lipid metabolism produces less carbon dioxide. Based on our result that lipid-shift trend might contribute 
a better prognosis, a high-fat intake could be an attractive option in a high-calorie diet for ALS. Of course, the 
choice of nutrition must be cautiously made, depending on the patients’ metabolic profiles.
The definition we adopted for hypermetabolism is a high mREE/LSTM, rather than the popular global index, 
mREE/pREE, because pREE estimated by the Harris-Benedict equation is reportedly not appropriate for the 
metabolic assessment of Japanese  persons29. In our study, mREE/pREE positively correlated with LSTM, and 
thus mREE/pREE might be underestimated in patients with lower LSTM. Indeed, mREE/pREE was not found 
to be a beneficial prognostic factor in this study (Supplemental Fig. 2), contrary to previous  reports9,10. On the 
other hand, mREE/LSTM was also negatively associated with LSTM in this study, which may cause overestima-
tion of mREE/LSTM in patients with lower LSTM. However, high mREE/LSTM could reflect hypermetabolism 
more accurately than mREE/pREE in our cohort because mREE/LSTM was a poor prognostic factor in the 
normal-weight group, which was consistent with the previously reported fact that hypermetabolism was a poor 
prognostic  factor9,10. There is no universally accepted index for assessing hypermetabolism, and mREE/LSTM 
may be a useful index for metabolic assessment in the Japanese population.
This study has several limitations. One is the small sample size; each nutritional group had a small number 
of patients. Second, this study is a retrospective study and included only Japanese patients in a single-center. The 
definition of malnutrition and hypermetabolism may be different in other countries, and it is not clear whether 
the prognostic prediction from mREE/LSTM depends on %IBW in other countries and this study. Adjusting the 
reference value of mREE/LSTM and BMI might make the BMM index more universally available. Of note, there 
are few studies on prognostic models for ALS in Asia, and this study is  precious42. Third, we included patients 
at different stages with different reasons, such as close investigation, the introduction of therapeutic drugs and 
NPPV, and PEG. The validation of the timing of the BMM index in the clinical course is also required. Fourth, 
we did not perform a genetic test in most cases. Only one patient had the L106V mutation in the superoxide 
dismutase 1 (SOD1) gene, and this patient was in the hypermetabolic and normal-weight group and had a very 
high BMM index. The patient indeed showed a rapid progression. The relationship between genetic mutation 
and BMM index needs to be investigated in the future.
This is the first study to show that prognosis prediction by hypermetabolism varies depending on the nutrition 
status in patients with early ALS. The BMM index is a useful predictor of the prognosis, which could be referred 
to as the decision of interventions, such as PEG and NPPV, at an early stage to patients with a high BMM index.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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